Accordingly, our previous RNA sequencing data show that inhibition of ERK1/2 with ulixertinib reduces AURKB expression, while BRAF inhibition alone does not.55 Finally, AURKB not only plays an important role in chromosome segregation and cell division, but also has many substrates involved in apoptosis, including TP53.56 Together, these data suggest that combined AURKB and ERK1/2 inhibition slows cell growth and promotes apoptosis in BRAF-mutant advanced thyroid cancer cells and represents a promising therapeutic strategy for patients who do not respond to current therapies. The gene discussed is TP53; the disease is thyroid cancer.